Genekam Biotechnology

Executive Summary

Genekam Biotechnology, based in Duisburg, Germany, is a private diagnostics company specializing in real-time PCR kits for infectious diseases, with a focus on emerging viral threats such as H5N1 avian influenza and Nipah virus. Founded in 2005, the company has developed a real-time PCR kit for the H5N1 virus of cattle origin, which is currently causing outbreaks in the USA and the Netherlands. This positioned Genekam to capture near-term demand as governments and livestock operators seek rapid testing solutions. Additionally, the company is advancing a PCR kit for Nipah virus, a high-mortality pathogen with pandemic potential, diversifying its product portfolio and addressing unmet needs in global health security. Despite limited public financial disclosures and a small operational footprint, Genekam's focus on niche yet critical diagnostics and its active presence in international business development events suggest a strategic growth trajectory.

Upcoming Catalysts (preview)

• 2026-05Participation at SelectUSA 202665% success
• 2026-03H5N1 cattle-origin PCR kit sales surge during US outbreaks70% success
• 2026-09Nipah virus PCR kit development milestone or regulatory clearance45% success